第六章、結論
HBP1 可經由調控 NADPH 氧化酶次單位--p47phox來影響細胞內氧化還原的平 衡，抑制 EGFR 的活性。
EGFR EGF
SOS Ras Shc
gp91/NOX
p40 p47 p67 Rac p22
NADPH + O2
NADP+ + O2．
-PTP -PTP -S- -SOH (active) (inactive)
p47
phox gene HBP1參考資料
1. Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer. 2005 Jul;12(Suppl 1):S17-27.
2. Beier I, Dusing R, Vetter H, Schmitz U. Epidermal growth factor stimulates Rac1 and p21-activated kinase in vascular smooth muscle cells. Atherosclerosis. 2008
Jan;196(1):92-7.
3. Blinov ML, Faeder JR, Goldstein B, Hlavacek WS. A network model of early events in epidermal growth factor receptor signaling that accounts for combinatorial complexity.
BioSystems. 2006 Feb-Mar;83(2-3):136-51.
4. Cabodi S, Moro L, Bergatto E, Boeri Erba E, Di Stefano P, Turco E, Tarone G, Defilippi P. Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem Soc Trans. 2004 Jun;32(Pt3):438-42.
5. Chan SK, Hill ME, Gullick WJ. The role of the epidermal growth factor receptor in breast cancer. Journal of Mammary Gland Biology & Neoplasia. 2006 Jan;11(1):3-11.
6. Xie H, Pallero MA, Gupta K, Chang P, Ware MF, Witke W, Kwiatkowski DJ, Lauffenburger DA, Murphy-Ullrich JE, Wells A. EGF receptor regulation of cell motility: EGF induces disassembly of focal adhesions independently of the
motility-associated PLCgamma signaling pathway. J Cell Sci. 1998 Mar;111 ( Pt 5)(Pt 5):615-24.
7. Xie W, Paterson AJ, Chin E, Nabell LM, Kudlow JE. Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of
transgenic mice inhibits pubertal mammary duct development. Mol Endocrinol. 1997 Nov;11(12):1766-81.
8. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M.
The epidermal growth factor receptor: From development to tumorigenesis.
Differentiation. 2007 Nov;75(9):770-87.
9. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008 Mar 13;358(11):1160-74.
10. Charest A, Wagner J, Jacob S, McGlade CJ, Tremblay ML.
Phosphotyrosine-independent binding of SHC to the NPLH sequence of murine protein-tyrosine phosphatase-PEST. evidence for extended phosphotyrosine
binding/phosphotyrosine interaction domain recognition specificity. J Biol Chem. 1996 Apr 5;271(14):8424-9.
11. Buffin-Meyer B, Crassous PA, Delage C, Denis C, Schaak S, Paris H. EGF receptor transactivation and PI3-kinase mediate stimulation of ERK by
alpha(2A)-adrenoreceptor in intestinal epithelial cells: A role in wound healing. Eur J Pharmacol. 2007 Nov 28;574(2-3):85-93.
12. Wolf-Yadlin A, Kumar N, Zhang Y, Hautaniemi S, Zaman M, Kim HD, Grantcharova V, Lauffenburger DA, White FM. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol. 2006;2:54.
13. Brandt B, Meyer-Staeckling S, Schmidt H, Agelopoulos K, Buerger H. Mechanisms of egfr gene transcription modulation: Relationship to cancer risk and therapy
response.[erratum appears in clin cancer res. 2007 jun 15;13(12):3759]. Clinical Cancer Research. 2006 Dec 15;12(24):7252-60.
14. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer. 2007 May;7(5):389-97.
15. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients.
Endocr Rev. 1992 Feb;13(1):3-17.
16. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients. Breast Cancer Research & Treatment. 1994 Jan;29(1):41-9.
17. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E. HER2
overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol. 2001;12 Suppl 1:S15-9.
18. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177-82.
19. Widakowich C, de Azambuja E, Gil T, Cardoso F, Dinh P, Awada A, Piccart-Gebhart M. Molecular targeted therapies in breast cancer: Where are we now? Int J Biochem Cell Biol. 2007;39(7-8):1375-87.
20. Babior BM. NADPH oxidase. Curr Opin Immunol. 2004 Feb;16(1):42-7.
21. Jin L, Burnett AL. NADPH oxidase: Recent evidence for its role in erectile dysfunction. Asian J Androl. 2008 Jan;10(1):6-13.
22. Reinehr R, Haussinger D. CD95 activation in the liver: Ion fluxes and oxidative signaling. Arch Biochem Biophys. 2007 Jun 15;462(2):124-31.
23. Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, Parthasarathy S, Petros JA, Lambeth JD. Hydrogen peroxide mediates the cell growth and
transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5550-5.
24. Blanchetot C, Tertoolen LG, den Hertog J. Regulation of receptor protein-tyrosine phosphatase alpha by oxidative stress. EMBO J. 2002 Feb 15;21(4):493-503.
25. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem.
2001;11(4):173-86.
26. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. oxidative stress:
Its effects on the growth, metastatic potential and response to therapy of breast cancer.
Breast Cancer Research. 2001;3(5):323-7.
27. Chen X, Abair TD, Ibanez MR, Su Y, Frey MR, Dise RS, Polk DB, Singh AB, Harris RC, et al. Integrin alpha1beta1 controls reactive oxygen species synthesis by
negatively regulating epidermal growth factor receptor-mediated rac activation. Mol Cell Biol. 2007 May;27(9):3313-26.
28. Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci. 2003 Sep;28(9):509-14.
29. den Hertog J, Groen A, van der Wijk T. Redox regulation of protein-tyrosine phosphatases. Archives of Biochemistry & Biophysics. 2005 Feb 1;434(1):11-5.
30. Joneson T, Bar-Sagi D. A Rac1 effector site controlling mitogenesis through superoxide production. J Biol Chem. 1998 Jul 17;273(29):17991-4.
31. Kyaw M, Yoshizumi M, Tsuchiya K, Izawa Y, Kanematsu Y, Tamaki T.
Atheroprotective effects of antioxidants through inhibition of mitogen-activated protein kinases. Acta Pharmacol Sin. 2004 Aug;25(8):977-85.
32. Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, Rhee SG. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. role in EGF
receptor-mediated tyrosine phosphorylation. J Biol Chem. 1997 Jan 3;272(1):217-21.
33. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science. 1995 Oct 13;270(5234):296-9.
34. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in
ras-transformed fibroblasts. Science. 1997 Mar 14;275(5306):1649-52.
35. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell. 2002 Feb;9(2):387-99.
36. Nimnual AS, Taylor LJ, Bar-Sagi D. Redox-dependent downregulation of rho by rac.
Nat Cell Biol. 2003 Mar;5(3):236-41.
37. Patel V, Rosenfeldt HM, Lyons R, Servitja JM, Bustelo XR, Siroff M, Gutkind JS.
Persistent activation of Rac1 in squamous carcinomas of the head and neck: Evidence for an EGFR/Vav2 signaling axis involved in cell invasion. Carcinogenesis. 2007 Jun;28(6):1145-52.
38. Zhao C, Du G, Skowronek K, Frohman MA, Bar-Sagi D. Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to ras activation by sos. Nat Cell Biol.
2007 Jun;9(6):706-12.
39. Xu D, Rovira II, Finkel T. Oxidants painting the cysteine chapel: Redox regulation of PTPs. Developmental Cell. 2002 Mar;2(3):251-2.
40. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol. 2003 Apr;15(2):247-54.
41. Yee AS, Paulson EK, McDevitt MA, Rieger-Christ K, Summerhayes I, Berasi SP, Kim J, Huang CY, Zhang X. The HBP1 transcriptional repressor and the p38 MAP kinase: Unlikely partners in G1 regulation and tumor suppression. Gene. 2004 Jul 7;336(1):1-13.
42. Classon M, Salama S, Gorka C, Mulloy R, Braun P, Harlow E. Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. Proc Natl Acad Sci U S A.
2000 Sep 26;97(20):10820-5.
43. Shih HH, Tevosian SG, Yee AS. Regulation of differentiation by HBP1, a target of the retinoblastoma protein. Mol Cell Biol. 1998 Aug;18(8):4732-43.
44. Sekkali B, Szabat E, Ktistaki E, Tolaini M, Roderick K, Harker N, Patel A, Williams K, Norton T, Kioussis D. Human high mobility group box transcription factor 1 affects thymocyte development and transgene variegation. J Immunol. 2005 Oct
15;175(8):5203-12.
45. Xiu M, Kim J, Sampson E, Huang CY, Davis RJ, Paulson KE, Yee AS. The
transcriptional repressor HBP1 is a target of the p38 mitogen-activated protein kinase pathway in cell cycle regulation. Mol Cell Biol. 2003 Dec;23(23):8890-901.
46. Bienz M, Clevers H. Linking colorectal cancer to wnt signaling. Cell. 2000 Oct 13;103(2):311-20.
47. Polakis P. Wnt signaling and cancer. Genes Dev. 2000 Aug 1;14(15):1837-51.
48. Kim J, Zhang X, Rieger-Christ KM, Summerhayes IC, Wazer DE, Paulson KE, Yee AS. Suppression of wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. requirement of the transcriptional repressor HBP1. J Biol Chem. 2006 Apr 21;281(16):10865-75.
49. Berasi SP, Xiu M, Yee AS, Paulson KE. HBP1 repression of the p47phox gene: Cell cycle regulation via the NADPH oxidase. Molecular & Cellular Biology. 2004 Apr;24(7):3011-24.
50. Yao CJ, Works K, Romagnoli PA, Austin GE. Effects of overexpression of HBP1 upon growth and differentiation of leukemic myeloid cells. Leukemia. 2005 Nov;19(11):1958-68.
51. Hunter CP. Gene silencing: Shrinking the black box of RNAi. Curr Biol. 2000 Feb 24;10(4):R137-40.
52. He L, Hannon GJ. MicroRNAs: Small RNAs with a big role in gene regulation.
Nature Reviews Genetics. 2004 Jul;5(7):522-31.
53. Sharp PA. RNAi and double-strand RNA. Genes Dev. 1999 Jan 15;13(2):139-41.
54. Di Fiore PP, Segatto O, Taylor WG, Aaronson SA, Pierce JH. EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science.
1990 Apr 6;248(4951):79-83.
55. Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL, Ethier SP. ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity on human mammary epithelial cells. Br J Cancer. 2000 Feb;82(3):666-74.
56. Sawaki M, Ito Y, Akiyama F, Tokudome N, Horii R, Mizunuma N, Takahashi S, Horikoshi N, Imai T, et al. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer. 2006;13(2):172-8.
57. Lin A, Rugo HS. The role of trastuzumab in early stage breast cancer: Current data and treatment recommendations. Current Treatment Options in Oncology. 2007 Feb;8(1):47-60.
58. Droge W. Free radicals in the physiological control of cell function. Physiol Rev.
2002 Jan;82(1):47-95.
59. Ray G, Husain SA. Oxidants, antioxidants and carcinogenesis. Indian J Exp Biol.
2002 Nov;40(11):1213-32.
60. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991 Feb 1;51(3):794-8.
61. Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann N Y Acad Sci. 2000;899:349-62.
62. Tonks NK, Diltz CD, Fischer EH. Purification of protein-tyrosine phosphatases from human placenta. Methods Enzymol. 1991;201:427-42.
63. Paulson KE, Rieger-Christ K, McDevitt MA, Kuperwasser C, Kim J, Unanue VE, Zhang X, Hu M, Ruthazer R, et al. Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer. Cancer Res. 2007 Jul 1;67(13):6136-45.
附錄 pBabe.puro 與 pSUPER.puro 載體
附錄、pBabe.puro 與 pSUPER.puro 載體
附圖 1-1 pBabe.puro 載體
資料來源：addgene (http://www.addgene.org/pgvec1)
附錄 pBabe.puro 與 pSUPER.puro 載體
附圖 1-2 pSUPER.puro 載體
資料來源：addgene (http://www.addgene.org/pgvec1)
謝誌
在兩年的跌跌撞撞下，終於完成了我的論文，這趟研究所旅程也總算能夠完美 的結束。首先，當然是感謝認真批閱的口試委員們—黃士懿教授、楊欣玲教授與李 明芬副教授。身為老師的第一個學生，想當初剛踏進實驗室時，映入眼簾的是一片 空蕩蕩的房間，沒有任何的實驗藥品、儀器，當然也無法進行任何的實驗。當同學 們在討論自己的實驗時，我只能在一旁傻笑。第二年的時候，終於有新的學妹加入 了，在原本只有兩個人的空間增添了一些人氣，而我，也不再是一個人面對一整張 大桌子，氣氛也瞬間熱鬧的許多。
在這兩年當中，想感謝的人很多，首先是實驗室的學妹豐姿和筱琪。已經習慣 一個人完成所有事情的我，當你們主動開口說要幫忙時，真的有點不太好意思。不 過漸漸地，我也感受到，很多事情真的需要大家共同合作來完成。很謝謝你們在我 忙碌時 也因為這樣，我的實驗才能夠順利的完成；再來還要感謝趙蓓敏老師實 驗室的學姊、同學與學弟妹，也因為有你們提供許多幫助，讓我的研究可以如期完 成；另外就是我的同學們，不論是技術上或是精神上都給予我很大的支持；另外還 有其他實驗室的學長姐們，在我不懂得時候也適時的提供指導與幫助。最後，要感 謝的人當然是實驗室永遠的大帥哥—黃俊瑩老師，不論是兩年前還是現在，我從來 沒有後悔過我的選擇。我想我應該算是很幸運，在一個完全陌生的環境中，有這麼 多的人熱心的協助、支持我，感謝你們讓我順利的完成學業。
最後，最要感謝的人是我親愛的爸爸媽媽，謝謝你們讓我無後顧之憂的唸完研 究所，我要將這份榮耀獻給你們，因為你們無怨無悔的付出，才有今天的我。